Reduction in Platelet Reactivity With Prasugrel 5 mg in Low-Body-Weight Patients Is Noninferior to Prasugrel 10 mg in Higher-Body-Weight Patients
David Erlinge(Lund University), Kenneth J. Winters(Eli Lilly (United States)), Dominick J. Angiolillo(University of Florida), David P. Foley(Beaumont Hospital), Stefan James(Uppsala University), Patricia Brown(Eli Lilly (United States)), Chunmei Zhou(Eli Lilly (United States)), Thomas O. Bergmeijer(St. Antonius Ziekenhuis), Henrik Wagner(Örebro University Hospital), Joseph A. Jakubowski(Indiana Biosciences Research Institute), David S. Small(Eli Lilly (United States)), Jurriën M. ten Berg(St. Antonius Ziekenhuis), Junxiang Luo(Eli Lilly (United States)), Brian A. Moser(Eli Lilly (United States))
Cited by 83
Related Papers
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS
|European Heart Journal|2017|3k
Targeted Temperature Management at 33°C versus 36°C after Cardiac Arrest
|New England Journal of Medicine|2013|2.8k